

# Contents

<b>Phosphodiesterase Inhibitors: History of Pharmacology</b> .....	1
Christian Schudt, Armin Hatzelmann, Rolf Beume, and Hermann Tenor	
<b>Phosphodiesterase Inhibitors: Factors That Influence Potency, Selectivity, and Action</b> .....	47
Sharron H. Francis, Miles D. Houslay, and Marco Conti	
<b>Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics</b> .....	85
Hermann Tenor, Armin Hatzelmann, Rolf Beume, Gezim Lahu, Karl Zech, and Thomas D. Bethke	
<b>Structural Insight into the Substrate Specificity of Phosphodiesterases</b> .....	121
Hengming Ke, Huanchen Wang, and Mengchun Ye	
<b>A Fission Yeast-Based Platform for Phosphodiesterase Inhibitor HTSs and Analyses of Phosphodiesterase Activity</b> .....	135
Didem Demirbas, Ozge Ceyhan, Arlene R. Wyman, and Charles S. Hoffman	
<b>The GAF-Tandem Domain of Phosphodiesterase 5 as a Potential Drug Target</b> .....	151
Joachim E. Schultz, Torsten Dunkern, Elvira Gawlitta-Gorka, and Gabriele Sorg	
<b>Small Molecule Allosteric Modulators of Phosphodiesterase 4</b> .....	167
Mark E. Gurney, Alex B. Burgin, Olafur T. Magnusson, and Lance J. Stewart	
<b>Regulation of Endothelial Barrier Function by Cyclic Nucleotides: The Role of Phosphodiesterases</b> .....	193
James Surapisitchat and Joseph A. Beavo	

<b>Phosphodiesterases as Targets for Intermittent Claudication</b> .....	211
Yongge Liu, Yasmin Shakur, and Junichi Kambayashi	
<b>Phosphodiesterase Inhibition in Heart Failure</b> .....	237
Matthew A. Movsesian and Rakesh C. Kukreja	
<b>Phosphodiesterases: Emerging Therapeutic Targets for Neonatal Pulmonary Hypertension</b> .....	251
Kathryn N. Farrow and Robin H. Steinhorn	
<b>Role of Phosphodiesterases in Adult-Onset Pulmonary Arterial Hypertension</b> .....	279
F. Murray, M.R. MacLean, and P.A. Insel	
<b>Treatment of Erectile Dysfunction and Lower Urinary Tract Symptoms by Phosphodiesterase Inhibitors</b> .....	307
Stefan Ückert and Christian G. Stief	
<b>Evaluation of the Therapeutic Utility of Phosphodiesterase 5A Inhibition in the <i>mdx</i> Mouse Model of Duchenne Muscular Dystrophy</b> .....	323
Justin M. Percival, Candace M. Adamo, Joseph A. Beavo, and Stanley C. Froehner	
<b>Phosphodiesterases as Targets for Modulating T-Cell Responses</b> .....	345
Elisa Bjørgo, Kristine Moltu, and Kjetil Taskén	
<b>Cyclic Nucleotides and Phosphodiesterases in Monocytic Differentiation</b> .....	365
Angie L. Hertz and Joseph A. Beavo	
<b>Phosphodiesterase Inhibitors in the Treatment of Inflammatory Diseases</b> .....	391
C.P. Page and D. Spina	
<b>Harnessing the Clinical Efficacy of Phosphodiesterase 4 Inhibitors in Inflammatory Lung Diseases: Dual-Selective Phosphodiesterase Inhibitors and Novel Combination Therapies</b> .....	415
Mark A. Giembycz and Robert Newton	
<b>Phosphodiesterases in the Central Nervous System: Implications in Mood and Cognitive Disorders</b> .....	447
Ying Xu, Han-Ting Zhang, and James M. O'Donnell	

<b>Therapeutic Potential of Phosphodiesterase Inhibitors in Parasitic Diseases</b>	487
Yasmin Shakur, Harry P. de Koning, Hengming Ke, Junichi Kambayashi, and Thomas Seebeck	
<b>Index</b>	511

Phosphodiesterases as Drug Targets

Francis, S.H.; Conti, M.; Houslay, M.D. (Eds.)

2011, XVIII, 522 p., Hardcover

ISBN: 978-3-642-17968-6